Get started
Insulet CorporationInsulet CorporationInsulet Corporation

Insulet Corporation

No trades
See on Supercharts
Overview
Financials News Ideas Discussions Technicals Forecast Seasonals Bonds

PODD chart


Full chart

PODD upcoming earnings

Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—

Key stats


Market capitalization
‪16.52 B‬USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
42.79
Basic EPS (TTM)
5.65USD
Net income (FY)
‪206.30 M‬USD
Revenue (FY)
‪1.70 B‬USD
Shares float
‪69.66 M‬
Beta (1Y)
1.40

Employees


Employees (FY)
‪3 K‬
Change (1Y)
+400 +15.38%
Revenue / Employee (1Y)
‪565.70 K‬USD
Net income / Employee (1Y)
‪68.77 K‬USD

About Insulet Corporation


Sector
Health Technology
Industry
Medical Specialties
CEO
James R. Hollingshead
Website
insulet.com
Headquarters
Acton
Founded
2000
FIGI
BBG000R7XX87
Insulet Corp. is a medical device company, which engages in the development, manufacture, and marketing of an insulin infusion system for people with insulin-dependent diabetes. It specializes in diabetes supplies, including the OmniPod System, as well as other diabetes related products and supplies such as blood glucose testing supplies, traditional insulin pumps, pump supplies, and pharmaceuticals. The company was founded by John L. Brooks III and John T. Garibotto in July 2000 and is headquartered in Acton, MA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—
‪0.00‬

Ideas



See all ideas 

PODD news



Technicals

Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

PODD highest yielding bonds


PODD5061895
Insulet Corporation 0.375% 01-SEP-2026
Yield to maturity
−9.70%
Maturity date
Sep 1, 2026

Explore more bonds 

Frequently Asked Questions


The current price of PODD is 237.44 USD — it has increased by 0.67% in the past 24 hours. Watch Insulet Corporation stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Insulet Corporation stocks are traded under the ticker PODD.
PODD stock has risen by 0.54% compared to the previous week, the month change is a 2.55% rise, over the last year Insulet Corporation has showed a 52.21% increase.
We've gathered analysts' opinions on Insulet Corporation future price: according to them, PODD price has a max estimate of 285.00 USD and a min estimate of 185.00 USD. Watch PODD chart and read a more detailed Insulet Corporation stock forecast: see what analysts think of Insulet Corporation and suggest that you do with its stocks.
PODD reached its all-time high on May 5, 2023 with the price of 335.91 USD, and its all-time low was 2.57 USD and was reached on Mar 9, 2009. View more price dynamics on PODD chart.
See other stocks reaching their highest and lowest prices.
PODD stock is 2.19% volatile and has beta coefficient of 1.40. Track Insulet Corporation stock price on the chart and check out the list of the most volatile stocks — is Insulet Corporation there?
Today Insulet Corporation has the market capitalization of ‪16.52 B‬, it has decreased by −2.97% over the last week.
Yes, you can track Insulet Corporation financials in yearly and quarterly reports right on TradingView.
Insulet Corporation is going to release the next earnings report on Nov 7, 2024. Keep track of upcoming events with our Earnings Calendar.
PODD earnings for the last quarter are 2.59 USD per share, whereas the estimation was 0.56 USD resulting in a 359.43% surprise. The estimated earnings for the next quarter are 0.78 USD per share. See more details about Insulet Corporation earnings.
Insulet Corporation revenue for the last quarter amounts to ‪488.50 M‬ USD, despite the estimated figure of ‪488.00 M‬ USD. In the next quarter, revenue is expected to reach ‪518.76 M‬ USD.
PODD net income for the last quarter is ‪188.60 M‬ USD, while the quarter before that showed ‪51.50 M‬ USD of net income which accounts for 266.21% change. Track more Insulet Corporation financial stats to get the full picture.
No, PODD doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 5, 2024, the company has ‪3.00 K‬ employees. See our rating of the largest employees — is Insulet Corporation on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. Insulet Corporation EBITDA is ‪348.20 M‬ USD, and current EBITDA margin is 17.25%. See more stats in Insulet Corporation financial statements.
Like other stocks, PODD shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Insulet Corporation stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Insulet Corporation technincal analysis shows the buy rating today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Insulet Corporation stock shows the buy signal. See more of Insulet Corporation technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.